Actuate Therapeutics (ACTU) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ACTU Actuate Therapeutics

Watchlist

6.770
-0.280-3.97%

Close Dec 20 16:00 ET

6.770
0.0000.00%

Post 17:17 ET

132.23MMarket Cap-4.65P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Actuate Therapeutics Inc - Statistical Significance Met on Primary Endpoints in Phase 2 Trial
ReutersDec 17 08:28 ET
Express News | Actuate Therapeutics Inc - Elraglusib in Combination With Gnp Shows Favorable Risk-Benefit Profile
ReutersDec 17 08:00 ET
Express News | Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
ReutersDec 17 08:00 ET
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
BenzingaDec 13 05:30 ET
Express News | Actuate Therapeutics to Be Added to Russell 2000® Index
ReutersNov 26 08:02 ET
Actuate Therapeutics to Be Added to Russell 2000 Index
GlobeNewswireNov 26 08:00 ET

Comments

Jaguar8

Dec 17 16:55

🟡Watchlist WEDNESDAY December 18,2024

NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 months✅
$Wearable Devices (WLDS.US)$ PR 12/17:...

Jaguar8

Dec 17 07:06

NEWS

$Actuate Therapeutics (ACTU.US)$
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
Tuesday, 17th December at 8:00 am
• Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall Survival
• Doubling of 1 Year Survival Rate and 37% Reduction in Risk of Death
• Two Month (29%) Increase in Median Overall Survival
• Multiple Patients with Complete Responses (CRs) and/or Partial Re...

BomBstar

Dec 16 03:57

$Actuate Therapeutics (ACTU.US)$ buy the dip?

Teddy123

Oct 29 22:55

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

$Actuate Therapeutics (ACTU.US)$
CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced that it will participate in “Webinar Wednesday” hosted b...